Article | March 24, 2026 OPDP’s 2026 Untitled Letters: Early Enforcement Trends in Prescription Drug Promotion Read More
Article | March 19, 2026 Enforcement Discretion for “No Artificial Colors” Food Labeling Claims Read More
Article | March 05, 2026 Event Recap: Negotiating Medical Device, Pharmaceutical, and Biotechnology Product Sales Contracts Read More
Article | February 23, 2026 Prepare for Impact: CCPA Risk Assessment Regulations Now in Effect Read More
Article | February 18, 2026 A Recent Challenge to FDA’s Approach to Dietary Supplements Claims Read More
Article | February 17, 2026 Sunshine Reporting Season Has Begun: Are You Meeting the Requirements? Read More
Article | February 10, 2026 San Francisco’s Ultra-Processed Foods Lawsuit Signals a New Enforcement Frontier Read More
Article | February 05, 2026 Navigating FDA Promotional Compliance: TEVIMBRA and Digital Brand Assets Read More
Article | January 27, 2026 Privacy and AI Heatmap for 2026: What Device & Drug Makers Should Watch in 2026 Read More
Article | January 15, 2026 What FDA’s TEMPO Pilot and CMS’s ACCESS Model Mean for Medical Device Manufacturers Read More
Article | January 08, 2026 Clarity in Complexity: The Benefits of a Business Stance Playbook Read More